Oxi 4503: Clinical Trials

3 trials of Oxi 4503, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 terminated. 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 13Completed 2, Terminated 1

Follow Oxi 4503: new trials by email Literature Review of Oxi 4503 trials Research Report on Oxi 4503

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS
OXi4503 - Leukemia, Myelogenous, Acute, Myelodysplastic Syndromes
Phase 1TerminatedUniversity of Florida182011-02-012017-08-08
Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden
Combretastatin A1 Diphosphate (OXi4503) - Neoplasm Metastasis
Phase 1CompletedMateon Therapeutics162009-07-012011-08-23
Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors
OXi4503 - Solid Tumors
Phase 1CompletedMateon Therapeutics402005-07-012011-10-31

Conditions studied

Carcinoma (1)  ·  Carcinoma, Hepatocellular (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Liver Neoplasms (1)  ·  Myelodysplastic Syndromes (1)  ·  Neoplasm Metastasis (1)

Sponsors

Mateon Therapeutics (2)  ·  University of Florida (1)

Countries

Australia (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Christopher R. Cogle, MD (1)  ·  Jason Lickliter, MD (1)  ·  Michael Brown, MD (1)  ·  Michael Millward, MD (1)  ·  Paul Mainwaring, MD (1)

Results publications

PMID 22235096, PMID 37816266